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Azoles are the primary class of antifungal agents used for evidence-based treatment and prevention of *Aspergillus* spp. diseases ([@R-2-1]). Azoles are the only class of mold-active agents that can be used orally, and voriconazole and posaconazole have improved the survival of patients at risk for invasive aspergillosis ([@R-2-2]--[@R-2-5]). However, recent reports describe the emergence of acquired resistance of *Aspergillus* spp. to azole compounds ([@R-2-6]--[@R-2-16]). Azole resistance may develop in patients with cavitary lung lesions, such as aspergilloma, or in patients with allergic bronchopulmonary aspergillosis who are treated with mold-active azoles, most notably, itraconazole ([@R-2-7],[@R-2-17]). In these patients, resistance is most commonly observed in *Aspergillus fumigatus*, and the isolates may be resistant to only itraconazole (ITZ) or exhibit a multi-azole-- or pan-azole--resistant phenotype. The phenotype depends on the underlying resistance mechanism, which commonly involves point mutations in the *cyp51A-*gene, the target for antifungal azoles ([@R-2-6]--[@R-2-8],[@R-2-10],[@R-2-11],[@R-2-17]--[@R-2-21]). A wide range of mutations was found in azole-resistant *Aspergillus* spp. isolates that were cultured from clinical samples from patients treated with azoles, and individual azole-resistant *Aspergillus* spp. colonies harbored different resistance mechanisms ([@R-2-7]).

In the Netherlands, a highly dominant resistance mechanism was found in isolates from epidemiologically-unrelated patients ([@R-2-6],[@R-2-9]). The dominant resistance mechanism consisted of a substitution of leucine for histidine at codon 98 of the *cyp51A-*gene in combination with a 34-bp tandem repeat in the promoter region of this gene (TR/L98H) ([@R-2-6],[@R-2-11]). The corresponding phenotype showed resistance to itraconazole and intermediate susceptibility or resistance to voriconazole, posaconazole, or both ([@R-2-6],[@R-2-20]). TR/L98H isolates were recovered from azole-treated and azole-naive patients with *Aspergillus* spp. diseases ([@R-2-6],[@R-2-9],[@R-2-10],[@R-2-22]--[@R-2-24]). Azole resistance may be associated with a high probability of azole treatment failure, a possibility that is supported by preclinical evidence ([@R-2-7],[@R-2-9],[@R-2-22]--[@R-2-26]).

On the basis of the above-mentioned observations, we hypothesized that resistance might have emerged as a consequence of exposure of *A. fumigatus* to azole fungicides in the environment ([@R-2-27]). Preliminary studies indeed showed that *A. fumigatus* isolates harboring TR/L98H could be recovered from the environment ([@R-2-28],[@R-2-29]). Furthermore, TR/L98H isolates were cross-resistant to certain azole fungicides ([@R-2-27],[@R-2-28]).

The spread and prevalence of azole resistance in clinical *A. fumigatus* isolates are unknown. Various studies in the Netherlands that have analyzed *Aspergillus* spp. culture collections indicate that the prevalence ranges from 1.8% to 12.8% ([@R-2-6],[@R-2-30],[@R-2-31]). Obtaining insight into the spread of azole resistance is essential for determining the implications of resistance for patient management strategies and public health. We therefore conducted a prospective surveillance study in 7 university medical centers in the Netherlands.

Methods
=======

Study Design
------------

All *Aspergillus* spp. isolates cultured from clinical samples that were processed in the 7 university medical microbiology laboratories were routinely screened for the presence of azole resistance, irrespective of the clinical relevance of the culture result. The University Medical Centers are located in 7 different cities in the Netherlands, and clinical isolates were screened during a 20-month period (June 2007--January 2009). Patient data were recorded in a Web-based database. An online questionnaire was completed for every collected isolate. The questionnaire included questions about isolate characteristics (species identification and date of isolation) and patient characteristics (age, sex, and underlying disease).

Screening ITZ Agar Slants
-------------------------

*Aspergillus* spp. colonies that grew in primary cultures were subcultured on Sabouraud agar slants supplemented with 4 mg/L of ITZ and incubated at 35°C--37°C. The colonies' ability to grow on the ITZ agar slants was assessed after 48 hours of incubation. For every isolate that was able to grow on the ITZ agar slants (ITZ positive), the primary culture isolate was sent to the Radboud University Nijmegen Medical Center for further analysis. Isolates that failed to grow on the ITZ agar slants (ITZ negative) were not analyzed. However, for all isolates that were screened, the online questionnaire was completed. At the screening sites, the *Aspergillus* spp. isolates were identified to species level by conventional methods, i.e., thermotolerance and macroscopic and microscopic assessment of culture morphologic features.

Proficiency Testing
-------------------

The ITZ agar slants were prepared at the Radboud University Nijmegen Medical Center and distributed to the other medical microbiology laboratories. Each center was provided with a protocol and a set of 6 *A. fumigatus* isolates. Four isolates were resistant to ITZ (MIC \>16 mg/L), while 2 were susceptible (ITZ MICs 0.125 and 0.25 mg/L). The centers were blinded for the resistance profiles and were asked to determine the ability of the isolates to grow on the ITZ agar slants.

Analysis of ITZ-positive Isolates
---------------------------------

Every ITZ-positive isolate was analyzed for certain phenotypic and genotypic features. The phenotypic analysis included the morphologic features of the isolate and susceptibility testing according to established standards ([@R-2-32]) by using a broth microdilution format. MICs were determined for ITZ, voriconazole, and posaconazole. Genotypic analyses were performed by complete sequencing of the *cyp51A* gene by using the reference sequence of strain no. AF338659 from GenBank.

For the confirmed ITZ-positive isolates, additional patient data that included azole exposure \<3 months before the date of isolation of the resistant isolate and the presence of *Aspergillus* spp. disease were requested from the treating physician. Patients with cancer and invasive aspergillosis were classified according to the revised European Organization for Research and Treatment of Cancer/Mycoses Study Group definitions ([@R-2-33]). In addition, patient data were collected on treatment and outcome 3 months after diagnosis.

Statistical Analysis
--------------------

Statistical analyses were performed by using SPSS version 17.0 (IBM, Somers, NY, USA). Analyses consisted of χ^2^ tests and a calculation of the κ coefficient.

Results
=======

Proficiency Testing
-------------------

Four of 6 control *A. fumigatus* isolates were resistant to ITZ and expected to grow on the ITZ agar slants, while the remaining 2 isolates were ITZ susceptible and should not grow on the ITZ agar slants. The 4 isolates with the azole-resistant phenotype harbored the TR/L98H resistance mechanism. For 3 ITZ-positive and the 2 ITZ-negative isolates, 100% agreement was found between the 7 centers. For 1 ITZ-positive isolate, the assessment of growth on the ITZ agar slant was incorrect from 3 centers; this isolate was a slowly sporulating *A. fumigatus* isolate. The κ coefficient calculated to assess the reproducibility of the method was 0.81 ([@R-2-34]).

Mycology
--------

During June 2007 through January 2009, we screened 2,062 *Aspergillus* spp. isolates from 1,385 patients for azole resistance using the ITZ agar slants. Most isolates were identified as *A. fumigatus* (1,792/2,062 \[86.9%\]) ([Table 1](#T-2-1){ref-type="table"}). For 50 (2.5%) *Aspergillus* spp. isolates, species identification was not done. Most *Aspergillus* spp. isolates were isolated from respiratory samples; 1,461 of 2,062 (70.9%) were from sputum cultures, and 60 (2.9%) were from cultures derived from clinical specimens obtained from sterile sites (i.e., tissue specimens obtained through invasive procedures or at autopsy) ([Table 1](#T-2-1){ref-type="table"}).

###### Characteristics of screened susceptible and resistant isolates of *Aspergillus* spp., the Netherlands, 2007--2009\*

  Source and species   No. (%) susceptible, n = 1,978   No. (%) resistant, n = 84
  -------------------- -------------------------------- ---------------------------
  Specimen source                                       
  Sputum               1,397 (70.6)                     64 (76.2)
  Ear swab             176 (8.9)                        3 (3.6)
  BAL fluid            97 (4.9)                         6 (7.1)
  Bronchus secretion   66 (3.3)                         2 (2.4)
  Throat/nasal swab    66 (3.3)                         1 (1.2)
  Tissue               55 (2.8)                         5 (6.0)
  Skin swab/nail       38 (1.9)                         1 (1.2)
  Mouth wash           26 (1.3)                         1 (1.2)
  Pus/wound swab       16 (0.8)                         1 (1.2)
  Bronchial wash       11 (0.6)                         0
  Feces                8 (0.4)                          0
  Unknown              22 (1.1)                         0
                                                        
                                                        
  Species                                               
  *A. fumigatus*       1,710 (86.5)                     82 (97.6)
  *A. flavus*          98 (5.0)                         0
  *A. niger*           52 (2.6)                         2 (2.4)
  *A. terreus*         35 (1.8)                         0
  *A. nidulans*        14 (0.7)                         0
  *A. versicolor*      13 (0.7)                         0
  *A. glaucus*         6 (0.3)                          0
  Unknown              50 (2.5)                         0

\*BAL, bronchoalveolar lavage.

Ninety isolates were able to grow on the ITZ agar slants and were sent to the Radboud University Nijmegen Medical Center for further analyses. In vitro susceptibility testing showed that for 84 (93.3%) of 90 ITZ-positive isolates, the MIC of ITZ was \>2 mg/L, which was considered resistant ([@R-2-20]). Most ITZ-positive isolates also exhibited non--wild-type susceptibility profiles to voriconazole and posaconazole. A resistant phenotype for voriconazole (\>2 mg/L) and posaconazole (\>0.5 mg/L) was observed in 67/84 (79.8%) and 14/84 (16.7%) of ITZ-positive isolates, respectively. An intermediate susceptibility profile (2 mg/L for voriconazole and 0.5 mg/L for posaconazole) was observed in 12/84 (14.3%) and 44/84 (52.4%) of ITZ-positive isolates, respectively ([Table 2](#T-2-2){ref-type="table"}) ([@R-2-20]).

###### Characteristics of itraconazole-positive *Aspergillus fumigatus* isolates, the Netherlands, 2007--2009\*

  No. isolates   Mutations in the *Cyp51A*gene   Median MIC, mg/L (range)                
  -------------- ------------------------------- -------------------------- ------------ ----------------
  74             TR/L98H†                        \>16 (16--\>16)            8 (1--16)    0.5 (0.25--2)
  1              G54W†                           \>16                       0.5          \>16
  1              P216L†                          16                         2            0.5
  1              F219I†                          \>16                       0.25         0.25
  1              Series‡                         \>16                       \>16         1
  4              None                            \>16 (16--\>16)            4 (0.5--4)   0.2 (0.125--1)

\*In vitro susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38A2 method ([@R-2-32]). †Mutations that have previously been shown to be associated with azole resistance in *A. fumigatus* ([@R-2-7],[@R-2-20],[@R-2-21]). ‡Series of mutations in *Cyp51A*-gene: F46Y, G89G, M172V, N248T, D255E, L358L, E427K, and C454C ([@R-2-8]).

Sequence-based identification classified 82 ITZ-positive isolates as *A. fumigatus* and 2 as *A. niger.* Sequencing of the *cyp51A* gene showed a substitution of leucine for histidine at codon 98 in combination with a 34-bp tandem repeat in the gene promoter in 74 (90.2%) of 82 resistant *A. fumigatus* isolates ([Table 2](#T-2-2){ref-type="table"}). Other *cyp51A* mutations were found in 3 isolates (substitutions G54W, P216L, and F219I) ([Table 2](#T-2-2){ref-type="table"}) ([@R-2-7],[@R-2-8],[@R-2-20],[@R-2-21]). In 1 isolate, a series of mutations was found, and in the remaining 4 azole-resistant *A. fumigatus* isolates (4.9%), no mutations were found in the *cyp51A* gene ([@R-2-8]). Because *A. niger* has no known resistance mechanisms, the 2 azole-resistant *A. niger* isolates were not further analyzed.

Prevalence of Azole Resistance
------------------------------

A median of 100 isolates were screened each month, with a range of 78--140 isolates per month. The total number of screened clinical isolates per center ranged from 130 to 449 and were recovered from 84 to 238 patients. The collection of isolates over the study period and the distribution of the recovery of resistant isolates are shown in [Figure 1](#F-2-1){ref-type="fig"}. Overall, 82 (4.6%) of 1,792 screened *A. fumigatus* isolates were azole resistant. The per-patient analysis showed a prevalence of 5.3%. [Figure 2](#F-2-2){ref-type="fig"} shows the prevalence of resistance in *A. fumigatus* per center. The prevalence of azole resistance in *A. niger* was 3.8%. No seasonal variation was observed.

![Number of screened *Aspergillus* spp. isolates per month (bars) and prevalence (%) of azole resistance (line), the Netherlands, 2007--2009. ITZ, itraconazole.](11-0226-F1){#F-2-1}

![Prevalence (%) of azole-resistant *Aspergillus fumigatus* infections in university medical centers, the Netherlands, 2007--2009.](11-0226-F2){#F-2-2}

Patient Characteristics
-----------------------

The screened *A. fumigatus* isolates were cultured from 1,192 patients, while other *Aspergillus* spp. isolates were recovered from 193 patients. Among the patients who harbored *A. fumigatus* isolates, the predominant underlying diseases were cystic fibrosis (382/1,192 \[32.1%\]) and other pulmonary diseases (265/1,192 \[22.2%\]) Almost 12% (138/1,192) of the *A. fumigatus* isolates were from patients who had hematologic/oncologic diseases. The distribution of underlying diseases is shown in [Table 3](#T-2-3){ref-type="table"}.

###### Underlying diseases of patients from whom azole-susceptible and -resistant *Aspergillus fumigatus* isolates were recovered, the Netherlands, 2007--2009

  Underlying condition                           No. (%) patients with susceptible isolates, n = 1,129   No. (%) patients with resistant isolates, n = 63   p value\*
  ---------------------------------------------- ------------------------------------------------------- -------------------------------------------------- -----------
  Cystic fibrosis                                365 (32.3)                                              17 (27.0)                                          0.38
  Pulmonary disease, excluding cystic fibrosis   251 (22.2)                                              14 (22.2)                                          1.00
  Hematologic/oncologic disease                  125 (11.1)                                              13 (20.6)                                          0.02
  Otorhinolaryngologic disease                   63 (5.6)                                                3 (4.8)                                            0.78
  Internal disease                               85 (7.5)                                                8 (12.7)                                           0.14
  Solid organ transplantation                    26 (2.3)                                                2 (3.2)                                            0.66
  Intensive care unit patient                    31 (2.7)                                                2 (3.2)                                            0.84
  Cardiac disease                                9 (0.8)                                                 1 (1.6)                                            0.50
  Chronic granulomatous disease                  5 (0.4)                                                 0                                                  0.60
  Postoperative condition                        23 (2.0)                                                1 (1.6)                                            0.81
  Neurologic disease                             2 (0.2)                                                 0                                                  0.74
  Disease in children, not specified             4 (0.4)                                                 0                                                  0.64
  Dermatologic disease                           6 (0.5)                                                 1 (1.6)                                            0.29
  Other                                          91 (8.1)                                                1 (1.6)                                            
  Unknown                                        43 (3.8)                                                0                                                  

\*χ^2^ test.

Characteristics of Patients with Azole-Resistant Isolates
---------------------------------------------------------

The 82 confirmed ITZ-resistant *A. fumigatus* isolates were recovered from 63 patients. The patients' ages ranged from 1 to 85 years, with a mean age of 48.9 years. The sex distribution was equal.

Overall, the distribution of underlying diseases in patients with an ITZ-resistant isolate was similar to that observed in the group with ITZ-susceptible isolates, with 1 exception. In the group of patients with ITZ-resistant isolates, significantly more patients had hematologic/oncologic diseases than in the group that harbored ITZ-susceptible isolates (13/63 \[20.6%\] and 125/1,129 \[11.1%\], respectively; p\<0.05; [Table 3](#T-2-3){ref-type="table"}).

*Aspergillus* disease caused by an ITZ-resistant isolate was diagnosed in 23 patients (36%). Invasive aspergillosis was diagnosed in 8 patients (13%), 6 with confirmed and 2 with probable cases (Table 4). Four of these patients were azole naive, and 1 patient had been previously treated with fluconazole, which has no activity against *Aspergillus* species. All *A. fumigatus* isolates from patients with azole-resistant invasive aspergillosis harbored the TR/L98H resistance mechanism ([Table 4](#T-2-4){ref-type="table"}). All 5 patients who were treated with voriconazole monotherapy died within 3 months of receiving a positive culture result. For 3 patients, voriconazole therapy was switched to another class of antifungal compounds, i.e., echinocandin, polyene, or both, but only 1 of those 3 patients survived. Overall, 7 (87.5%) of 8 patients with azole-resistant aspergillosis died within 3 months ([Table 4](#T-2-4){ref-type="table"}).

###### Characteristics of patients with azole-resistant invasive aspergillosis, the Netherlands, 2007--2009\*

  Patient age, y/sex   Underlying disease                                                                     Disease                                  No. positive cultures†   Resistance mechanism   VCZ MIC, mg/L   Prior azole treatment (duration)‡   Treatment§           Outcome at 12 wk
  -------------------- -------------------------------------------------------------------------------------- ---------------------------------------- ------------------------ ---------------------- --------------- ----------------------------------- -------------------- ------------------
  66/M                 Lung carcinoma                                                                         Proven pulmonary aspergillosis           1                        TR/L98H                4               None                                VCZ                  Died
  59/M                 Hematologic malignancy, allo-SCT, GvHD                                                 Proven pulmonary aspergillosis           4                        TR/L98H                8               VCZ (\>1 mo)                        VCZ                  Died
  54/M                 Acute myeloid leukemia, relapse, allo-HSCT                                             Proven pulmonary aspergillosis           1                        TR/L98H                8               ITZ (2--4 wk)                       VCZ                  Died
  50/M                 Non-Hodgkin lymphoma, allo-SCT, GvHD, lung cavities                                    Probable pulmonary aspergillosis         2                        TR/L98H                16              VCZ (\>1 mo)                        VCZ                  Died
  36/F                 Breast carcinoma with metastasis                                                       Probable pulmonary aspergillosis         1                        TR/L98H                1               None                                VCZ                  Died
  13/F                 Non-Hodgkin lymphoma                                                                   Proven pulmonary and CNS aspergillosis   1                        TR/L98H                16              None                                VCZ, CAS, AMB        Died
  58/M                 Liver transplantation for hepatic failure after methotrexate treatment for arteritis   Proven pulmonary and CNS aspergillosis   5                        TR/L98H                2               None                                AMB, VCZ             Died
  60/M                 Acute myeloid leukemia, allo-SCT, GvHD                                                 Proven pulmonary and CNS aspergillosis   3                        TR/L98H                4               FCZ (1--2 wk)                       VCZ, CAS, AMB, POS   Survived

\*VCZ, voriconazole; allo-SCT, allogeneic hematopoietic stem cell transplantation; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; ITZ, itraconazole; CNS, central nervous system; CAS, caspofungin; AMB, amphotericin B; FCZ, fluconazole; POS, posaconazole. † All cultures were *Aspergillus fumigatus.* ‡Azole treatment \<12 wk before the first culturing of an azole-resistant isolate. §Azole treatment after first culturing of resistant isolate.

Noninvasive *Aspergillus* spp. disease with an ITZ-resistant isolate was diagnosed in 15 patients. Five patients had cystic fibrosis and allergic bronchopulmonary aspergillosis. Six patients had an aspergilloma; of these patients, 2 were immunocompromised, 1 because of AIDS and 1 because of Job syndrome. Three patients sought treatment for otomycosis; 1 patient had *Aspergillus* spp. sinusitis. Data on previous exposure to azoles were available for 14 patients with noninvasive *Aspergillus* spp. disease; and 9 (64.2%) of these patients were azole naive. The TR/L98H mutation was the dominant resistance mechanism, because it was present in 12 (80%) of 15 isolates. Overall, 14 (64.3%) of 22 patients with azole-resistant *Aspergillus* spp. disease and known status of azole exposure were azole naive at the time the resistant isolate was cultured.

Discussion
==========

Azole resistance is widespread in clinical *A. fumigatus* isolates in the Netherlands, and resistant isolates were found at all participating university medical centers. The overall prevalence was 5.3%, which is in a similar range as observed in the fungus culture collection of the Radboud University Nijmegen Medical Center ([@R-2-6]). However, the prevalence varied widely between the centers, with 1 center showing azole resistance in 10 (9.5%) of 105 patients with a positive *Aspergillus* spp. culture. In a previous study, we reported a resistance prevalence of 12.8% among *A. fumigatus* isolates sent to our department by other hospitals in the Netherlands ([@R-2-6]). This higher resistance rate may have been due to a different selection of isolates. In this study, all *Aspergillus* spp. isolates cultured in the participating laboratories were screened for resistance, irrespective of their clinical relevance, while in our previous study the isolates that were sent to Nijmegen were from patients with *Aspergillus* spp. diseases for whom antifungal therapy was not successful ([@R-2-6]).

Two other studies have investigated the prevalence of azole resistance in *Aspergillus* spp. in the Netherlands. One study investigated a collection of 170 clinical *A. fumigatus* isolates recovered from 114 patients from 21 different medical centers in 1945--1998 ([@R-2-30]). Three (1.8%) isolates were resistant to ITZ and were later found to harbor the TR/L98H resistance mechanism. These were the first TR/L98H isolates recovered in the Netherlands ([@R-2-6]). Another study investigated the prevalence of azole-resistant *Aspergillus* spp. isolates in the Netherlands by using a collection of 209 unselected clinical *A. fumigatus* isolates obtained over a 6-month period in 2005 ([@R-2-31]). Only 4 azole-resistant isolates were found, which corresponds with a prevalence of 1.9% ([@R-2-31]). The low prevalence may be because of the methods used. We used ITZ-containing agar-slants to select for resistant isolates, which enables detection of resistant colonies even in the presence of multiple azole-susceptible colonies. Although Klaassen et al. ([@R-2-31]) did not explain how isolates were obtained, azole-resistant colonies could have been missed if regular culture media were used ([@R-2-22],[@R-2-31]). A *κ*coefficient of 0.81 indicates that screening for azole resistance by using agar supplemented with ITZ is a highly reproducible method and appears to be a feasible approach for screening for azole resistance and for surveillance studies ([@R-2-34]).

Most (74/82 \[90.2%\]) of the azole-resistant isolates in our study were found to possess the TR/L98H mutation in the *cyp51A*-gene, which is a similar proportion as reported previously ([@R-2-6]). Previous studies have suggested that the probability of 2 genomic changes developing during azole therapy is highly unlikely and that exposure of *A. fumigatus* to azoles in the environment may be a possible route of resistance development ([@R-2-6],[@R-2-27],[@R-2-28]). *A. fumigatus* isolates harboring the TR/L98H resistance mechanism were recovered from the environment and were genetically related to TR/L98H-containing clinical isolates ([@R-2-28]). This mode of resistance development implies that previous exposure of patients to azole compounds is not a prerequisite. Indeed, our study shows that 64% of patients with an azole-resistant isolate have no history of previous azole exposure during the 3 months before culturing the isolate. This finding supports the proposed environmental route of resistance development.

The prevalence and spread of TR/L98H in *A. fumigatus* in other countries are largely unknown. A recent study by Mortensen et al. showed that 8% of environmental *A. fumigatus* isolates in Denmark harbored the TR/L98H resistance mechanism, which indicates that TR/L98H may be spreading ([@R-2-29]). Because in vitro susceptibility testing of *A. fumigatus* is not routinely performed in most laboratories, international surveillance studies are warranted.

Most TR/L98H isolates were resistant to voriconazole (79%), but a broad range of MICs was observed that varied from 1 mg/L to 16 mg/L. Reasons for this variation remain unclear. TR/L98H isolates may have developed additional mutations that confer voriconazole resistance but that are not associated with the *cyp51A* gene. Another possibility is that the tandem repeat, which serves as a transcriptional enhancer, causes varying levels of up-regulation of the *cyp51A* gene. This up-regulation may result in differences in the voriconazole phenotype. More research is needed to gain insight into this phenomenon.

The outcome for patients with azole-resistant invasive aspergillosis was dismal, with a mortality rate of 88%. None of the patients who were treated with voriconazole monotherapy were alive at 3 months; of 3 patients whose treatment was switched to another class of antifungal drugs, only 1 survived. A critical issue for future study is whether azole resistance is a determinant of the poor clinical outcome of patients with azole-resistant aspergillosis. A previously reported case series of patients with primarily noninvasive *Aspergillus* spp. disease indicated that azole resistance was associated with treatment failure ([@R-2-7]). However, establishing a relation between resistance and treatment outcome in invasive aspergillosis is complex because of the multiple factors that contribute to treatment outcome, including underlying disease, drug exposure, timing and accuracy of diagnosis, and timing of antifungal therapy. Furthermore, data are lacking on the effects of in vitro susceptibility patterns of *Aspergillus* spp. isolates on treatment outcomes. This relationship was recently described by using *Aspergillus* spp. isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network ([@R-2-35]). The 12-week mortality rate for patients with culture-positive confirmed or probable invasive aspergillosis was 53% ([@R-2-35]). For patients with azole-susceptible *A. fumigatus* aspergillosis treated with voriconazole, the proportion of deaths was 48% (J.W. Baddley, pers. comm.).

In a study by Herbrecht et al. ([@R-2-2]), a subset of 51 modified-intent-to-treat patients with definite (43 patients) or probable (8 patients) invasive aspergillosis had a positive culture with *A. fumigatus* with a wild-type susceptibility. The all-cause proportion of deaths in this group at 12 weeks was 39% (P. Troke, pers. comm.). Both these analyses show a lower death rate than observed in our study, which indicates that azole resistance may be associated with a poor outcome. The median MIC of voriconazole in the 8 patients with azole-resistant invasive aspergillosis was 4 mg/L, which is resistant ([@R-2-20]). Effects of an elevated voriconazole MIC on treatment outcome were supported by preclinical experimental results, in which mice infected with an *A. fumigatus* isolate that had a voriconazole MIC of 2 mg/L required a 2-fold higher voriconazole dose than did mice infected with a wild-type isolate to achieve a comparable survival rate ([@R-2-25]).

The low survival rate of patients whose treatment was switched from azole therapy to nonazole therapy could be due to the delay of initiation of treatment with an effective alternative drug or to the presence of cerebral disease. Overall, the number of patients with azole-resistant aspergillosis in our study was low, and additional studies are needed to confirm the relation between azole resistance and treatment failure.

Because specimens from patients with invasive aspergillosis seldom produce positive cultures, our study underestimates the number of azole-resistant cases. The diagnosis of azole resistance in culture-negative cases is a challenge because current biomarkers, such as galactomannan and 1,3-β-[D]{.smallcaps}-glucan, do not enable species identification, let alone in vitro susceptibility testing. Molecular tools have been shown to be able to detect mutations associated with azole resistance directly in tissue ([@R-2-36]) or in respiratory specimens ([@R-2-37]) but are not yet suitable for use in routine patient care. Molecular tools need to be developed that enable the rapid detection of multiple mutations, although only known mutations can be detected.

Our study shows that azole resistance in clinical *A. fumigatus* isolates is widespread in the Netherlands and that the survival rate of patients with azole-resistant invasive aspergillosis is low. The dominance of the TR/L98H resistance mechanism and the high proportion of resistant isolates recovered from azole-naive patients support an environmental route of resistance development. We believe that continued surveillance is required in the Netherlands, as well as routine in vitro susceptibility testing of *A. fumigatus* isolates obtained from patients with *Aspergillus* spp. disease. International surveillance programs are also warranted to estimate the size of the emerging problem of azole resistance. Furthermore, the first-line therapy of patients with invasive aspergillosis should be reconsidered, at least in those centers with a high prevalence of azole resistance.
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